| Objective To separate and identify the different protein between ovarian carcinoma cell lines with directional and non-directional highly lymphatic metastasis by proteomics technology. Then check the expression of ERAP1,MRPS27,H3F3A,BFSP1 in ovarian carcinoma cell lines with different lymphatic metastasis.Methods The different protein between ovarian carcinoma cell lines with directional and non-directional highly lymphatic metastasis were separated and identified by PF2D-ESI/MS and nanoHPLC-ESI-TOF-MS separately. The expression of ERAP1,MRPS27,H3F3A,BFSP1 in ovarian carcinoma cell lines with different lymphatic metastasis were detected by realtime-PCR.Results 13 different proteins have been identified by PF2D-ESI/MS, they are Apolipoprotein E receptor 2, Huntingtin interacting protein, Adipocyte-derived leucine aminopeptidase variant, AF039655 NID, H3 histone, family 3A, protein, BFSP1 protein, AF090938 NID, hypothetical protein, Poly(A) binding protein, Candidatus Pelagibacter ubique HTCC1002,AX973019 NID. And 14 different proteins have been identified by nanoHPLC-ESI-TOF-MS, they are heterogeneous nuclear ribonucleoprotein H3 (hnRNP H3), Growth-regulated protein alpha precursor(CXCL1), Galectin-7(Gal-7), Migration inhibitoryfactor-related protein 14 (MRP-14), Serpin B3 (Squamous cell carcinoma antigen 1) (SCCA-1), Calmodulin-like protein 5, Alpha-enolase, precursor, Desmoplakin (DP), Heat-shock protein beta-1, Annexin A2, Protein POF1B.The expression level of ERAP1,H3F3A,MRPS27gene in SKOV3, SKOV3-PM2, SKOV3-PM3 SKOV3-PM4 cell sublines is down-regulate, The expression level of BFSP1 gene have no significant difference.This result does not match the result of ESI-MS.Conclusions The different protein between ovarian carcinoma cell lines with directional and non-directional highly lymphatic metastasis involve Cathepsin, matrix metalloproteinase, proteolytic ferment, signal transduction path and so on.ERAP1,MRPS27,H3F3A gene expression down-regulation is closely related with the directional highly lymphatic metastasis of ovarian carcinoma. |